Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGAU3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $33,168.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on December 22, 2025, with an ultimate completion date of January 14, 2026, carries no set-aside designation, indicating that DMS Pharmaceutical competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical supply chain, with established performance across diverse product categories including branded and generic prescription medications, biologics, and specialty pharmaceuticals. The company's selection as a regional prime vendor under the PPV-G GEN V program, formalized through a contract with a $499.999 billion ceiling value and completion date of December 31, 2036, demonstrates its capability to fulfill the specialized pharmaceutical requirements of military healthcare operations. The current delivery order for Stelara, an immunosuppressant biologic used in treating conditions such as psoriasis and inflammatory bowel disease, represents one of numerous delivery orders issued under this prime vendor contract to support ongoing Department of Defense medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FGAU3?
SPE2DR26FGAU3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FGAU3 worth?
The government has obligated $33,168 on SPE2DR26FGAU3.
Is contract SPE2DR26FGAU3 an order under another contract?
Yes. SPE2DR26FGAU3 is a delivery order under SPE2DR25D9371, an indefinite delivery contract.
Was contract SPE2DR26FGAU3 competed?
The extent of competition for SPE2DR26FGAU3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award